gsk1278863 and Body-Weight

gsk1278863 has been researched along with Body-Weight* in 1 studies

Trials

1 trial(s) available for gsk1278863 and Body-Weight

ArticleYear
Pharmacokinetics, pharmacodynamics and safety of single, oral doses of GSK1278863, a novel HIF-prolyl hydroxylase inhibitor, in healthy Japanese and Caucasian subjects.
    Drug metabolism and pharmacokinetics, 2015, Volume: 30, Issue:6

    This study was performed to evaluate the pharmacokinetics (PK), pharmacodynamics (PD) and safety of GSK1278863, a novel prolyl hydroxylase inhibitor, following a single oral administration of GSK1278863 from 10 to 100 mg or placebo in Japanese (n = 19), and 10, 25 and 100 mg in Caucasians (n = 14). Dose-proportional increases were observed in AUCinf of GSK1278863 in both ethnic groups, with a 1.3-1.5-fold higher exposure seen in Japanese relative to Caucasians for all doses. This difference in exposure can be mainly explained by the observed differences in body weights between the two groups. Statistically significant increases in erythropoietin (EPO), vascular endothelial growth factor (VEGF) and reticulocyte counts were observed in Japanese subjects after the 50 and 100 mg dose as compared to placebo. In Caucasians, similar to Japanese, EPO and VEGF levels were observed to be increased in response to the 100 mg dose. Drug-related adverse events, including headache and abdominal pain were reported in 3 Japanese subjects, while headache was reported in 3 Caucasians. In conclusion, GSK1278863 was well tolerated, with dose-proportional increases in exposure observed in both groups. There was no evidence of ethnic differences between Japanese and Caucasian with regard to PK or PD.

    Topics: Administration, Oral; Adult; Area Under Curve; Asian People; Barbiturates; Body Weight; Dose-Response Relationship, Drug; Enzyme Inhibitors; Erythropoietin; Glycine; Half-Life; Healthy Volunteers; Humans; Hypoxia-Inducible Factor-Proline Dioxygenases; Japan; Male; Metabolic Clearance Rate; Reticulocytes; Single-Blind Method; Vascular Endothelial Growth Factor A; White People; Young Adult

2015